2024-05-02T09:55:32-07:00 2023-06-30 952076568 Leaf & Cole LLP 2810 Camino Del Rio South Suite 200 San Diego CA 92108 990 2022-07-01 463481092 SAN DIEGO BIOMEDICAL RESEARCH INSTITUTE SAND 8582007156 3525 JOHN HOPKINS CT STE 200 SAN DIEGO CA 92121 JOANNA DAVIES President & CEO 2024-05-01 true JOANNA DAVIES 999009999 true JILL BRANCH P00727664 6192947200 X 2 AAL1 IAL1 FAL1 2022 2023-04-26 12:10:37Z JOANNA DAVIES 3525 JOHN HOPKINS CT STE 200 SAN DIEGO CA 92121 6229349 false X www.sdbri.org X 2013 CA The SDBRI mission is to find new ways to predict and prevent cancer, diabetes, autoimmune disease, neurological disorders and HIV infection, and to accelerate medical advances that maintain health and improve quality of life. 5 4 37 91456 7438 5439529 6089666 18149 91456 48227 0 5457678 6229349 0 0 2860757 2366595 0 0 3899220 5027412 6759977 7394007 -1302299 -1164658 931015 17549471 1991877 19774991 -1060862 -2225520 X The SDBRI mission is to find new ways to predict and prevent cancer, diabetes, autoimmune disease, neurological disorders and HIV infection, and to accelerate medical advances that maintain health and improve quality of life. false false 2869278 Cancer:A major question in cancer treatment remains, why do some people respond to treatment and others dont. Finding new ways to detect and treat cancer could potentially lead to cures that are currently unavailable to a majority of patients. At SDBRI scientists are developing a new technology to identify previously unidentifiable cancer-specific targets that might be used to design novel cancer fighting drugs. A Postdoctoral Fellow from India received salary and benefits while being trained at SDBRI in a variety of cellular immunology and sterile techniques to better understand techniques to help diagnose and treat cancer.DNA replication and disease DNA replicates in a highly organized way in healthy cells. However, in unhealthy cells, DNA replication is mis-regulated. SDBRI scientists are working to understand how DNA replication is mis-regulated in human disease in the hopes of finding new therapeutic approaches to preventing and reversing diseases such as cancer.Cells in our bodies eat internal parts of themselves to maintain their own health. This process, known as autophagy (spokeno-to-foh-jee), is essential for removing toxic material that causes diseases such as neurodegeneration and cancer. In autophagy, components inside cells are placed in a trash bag called the autophagosome which looks like a balloon. The autophagosome then fuses with the cells incinerator to decompose the transported toxic material. Scientists at SDBRI are working to understand how these complicated events are controlled in the hopes that interventions in these pathways might lead to novel treatments for disease. 1208472 91456 HIV/AIDS: The World Health Organization recently estimated that 36.7 million people live with HIV/AIDS worldwide with 1 million HIV-related deaths every year. New infections are estimated at an alarming 1.8 million worldwide. Developing a successful HIV vaccine is a major global health initiative. Research at SDBRI is focused on introducing novel designs to create an HIV vaccine that more people respond to. The SDBRI strategy of using HIV virus-like particles (VLPs) as a vaccine platform is showing great promise. In addition, over the past year SDBRI scientists have designed ways to identify factors that help the immune system to respond to HIV vaccines. This is very important because it might allow us to enhance the vaccine making it work in more people. SDBRI continues to participate in a multi-organization HIV vaccine research program. Our investigators work with scientists across the U.S. and in several foreign countries, including The Netherlands and Malaysia. A Staff Scientist from Malaysia received salary & benefits while being trained at SDBRI in a variety of cellular, molecular and biochemical techniques to better understand the human response to vaccines. 1067583 Multiple Sclerosis:Multiple Sclerosis is a debilitating autoimmune disease in which immune cells travel to the brain and spinal cord and destroy the protective coating that surrounds nerve fibers. Without the protective coating nerves are unable to send messages to different parts of the body and this causes an array of disorders including numbness in hands and feet, muscle weakness, fatigue, and blurred vision. It is estimated that there are 2.3 million people with MS worldwide. The goal of our cutting-edge research at SDBRI is to identify ways to manipulate and strengthen blood vessels so that the cells that cause multiple sclerosis (MS) are unable to enter the brain. In particular we seek to understand how the integrity of blood vessels in the brain is regulated by: (i) proteins of the extracellular matrix (ECM) that surround cells, and (ii) environmental stimuli such as mild hypoxia. By understanding these mechanisms, we can design new therapeutic approaches aimed at increasing blood supply and reducing vascular leak, thereby making blood vessels better equipped to protect against neurological damage. A Staff Scientist from Bangladesh and a Postdoctoral Fellow from Nepal received salary & benefits while being trained at SDBRI in cellular, molecular and biochemical techniques to learn how blood vessels can be strengthened and repaired and how we can use that information to stop and reverse MS. 1730616 6875949 true true false false false false false false false false true false false true true true true false false false false false false false false false false false false true false false false true false false false false false false false false false false false false false true 16 0 false 37 true true true false false false false false false 0 false false false false false false false X 5 4 false false false false false false false true true false false true true true true true true true true false CA X JOANNA DAVIES 8582007086 3525 JOHN HOPKINS CT STE 200 SAN DIEGO CA 92121 JOANNA DAVIES President & CEO 40.00 0.00 X X 214803 0 35559 DAVID GILBERT ASSOC PROFESSOR 40.00 0.00 222716 0 22032 JAMES BINLEY Professor 40.00 0.00 196116 0 41469 DAVID MILNER PROFESSOR 40.00 0.00 160678 0 38247 ROBERTO BACCALA ASSOC PROFESSOR 40.00 0.00 150000 0 11638 TAKANORI OTOMO PHD ASSOC PROFESSOR 40.00 0.00 116271 0 24440 BRUNO CONTI PROFESSOR 40.00 0.00 129151 0 2782 MARIA CECILIA G MARCONDES ASSOC PROFESSOR 40.00 0.00 102279 0 26300 CHRISTINE AUCIELLO ACCTING MGR 40.00 0.00 94716 0 23097 CARY THOMAS Chairman 1.00 0.00 X X 0 0 0 SHEILA FERGUSON Treasurer 1.00 0.00 X X 0 0 0 MARK HARGREAVES Director 1.00 0.00 X 0 0 0 RICHARD WOLTMAN Director 1.00 0.00 X 0 0 0 1386730 225564 8 false true false 0 6040808 48858 6089666 VENDOR SERVICES 900099 91456 91456 91456 48227 48227 0 0 0 0 0 0 0 0 6229349 91456 48227 0 0 0 0 910595 712498 198097 0 1388733 1339085 49648 178934 159654 19280 -288759 -191612 -97147 177092 158011 19081 6495 6495 73521 38073 35448 22470 22470 0 0 0 216801 178289 38512 0 53638 52332 1306 115944 110836 5108 0 2945495 2798538 146957 24016 19762 4254 0 0 0 0 85218 80957 4261 31154 29596 1558 LABORATORY SUPPLIES & SERVICES 796070 794524 1546 RESEARCH SUBCONTRACTS 483541 483541 OTHER EXPENSES 103869 45927 57942 MINOR EQUIPMENT 39038 37303 1735 30142 28635 1507 7394007 6875949 518058 0 86223 49152 0 478802 1111958 0 0 0 0 0 22169 18448 595911 287751 168875 308160 0 0 0 0 174946 16061753 931015 17549471 596526 1052551 334453 200000 21002 300323 100000 150000 1274349 17737664 1991877 19774991 X -1060862 -2225520 -1060862 -2225520 931015 17549471 -1164658 X false true X true true true X 4158429 5241067 5504252 5439529 6089666 26432943 0 0 4158429 5241067 5504252 5439529 6089666 26432943 0 26432943 0 1187 8438 9625 0 26442568 0.99960 0.99990 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 595911 287751 308160 308160 DEPOSIT 146020 RIGHT OF USE ASSET 15915733 16061753 DUE TO AFFILIATE 347477 Finance lease liability 45675 OPERATING LEASE LIABILITY 17344512 17737664 X 6229349 6229349 6229349 7394007 7394007 7394007 Part X : FIN48 Footnote The Institute believes that it has appropriate support for any tax positions taken, and as such, does not have any uncertain tax positions that are material to the financial statements. X false false false false false false false false false DAVID GILBERT ASSOC PROFESSOR 200716 22000 12946 9086 244748 DAVID MILNER PROFESSOR 160678 13110 25137 198925 JAMES BINLEY Professor 191116 5000 16294 25175 237585 JOANNA DAVIES President & CEO 214803 17456 18103 250362 ROBERTO BACCALA ASSOC PROFESSOR 150000 11250 388 161638 JOANNA DAVIES PRESIDENT OPERATING X 200000 200000 false true true BALLAD RESEARCH INSTITUTE Indirect aDVANCE X 347477 false true false 547477 BALLAD RESEARCH INSTITUTE Indirect - Pres 481753 Reimbursement of expenses false Form 990, Part III, Line 4d OTHER PROGRAM SERVICES 4: Multiple Sclerosis:Multiple Sclerosis is a debilitating autoimmune disease in which immune cells travel to the brain and spinal cord and destroy the protective coating that surrounds nerve fibers. Without the protective coating nerves are unable to send messages to different parts of the body and this causes an array of disorders including numbness in hands and feet, muscle weakness, fatigue, and blurred vision. It is estimated that there are 2.3 million people with MS worldwide. The goal of our cutting-edge research at SDBRI is to identify ways to manipulate and strengthen blood vessels so that the cells that cause multiple sclerosis (MS) are unable to enter the brain. In particular we seek to understand how the integrity of blood vessels in the brain is regulated by: (i) proteins of the extracellular matrix (ECM) that surround cells, and (ii) environmental stimuli such as mild hypoxia. By understanding these mechanisms, we can design new therapeutic approaches aimed at increasing blood supply and reducing vascular leak, thereby making blood vessels better equipped to protect against neurological damage. A Staff Scientist from Bangladesh and a Postdoctoral Fellow from Nepal received salary & benefits while being trained at SDBRI in cellular, molecular and biochemical techniques to learn how blood vessels can be strengthened and repaired and how we can use that information to stop and reverse MS. OTHER PROGRAM SERVICES 5: Diabetes:Type 2 diabetes: More than 1.9 billion adults are overweight, and over 600 million of these are obese. In addition, more than 42 million children under the age of 5 are overweight or obese. Obesity is a problem because it dramatically increases the risk of a variety of serious disorders including insulin resistance, type 2 diabetes, cardiovascular disease and cancer. The mechanism by which obesity leads to these disorders is not understood. At SDBRI, researchers are working to identify the cellular and molecular pathways the lead from obesity to insulin resistance and type 2 diabetes, and to cancer. SDBRI scientists are working together in collaborative groups to develop new treatments that can interrupt these pathways and prevent these diseases. Type 1 diabetes: Our scientists also work on type 1 diabetes, which is caused when the immune system accidentally kills the insulin-secreting cells that control blood sugar levels. Type 1 diabetes is diagnosed in children and young adults. SDBRI scientists have discovered a new piece of the immune system that might slow down and even reverse the progression of type 1 diabetes in young children. Ongoing work is focused on how these newly identified cells work and how they can be expanded. That information will be used to design new therapies to reverse type 1 diabetes. This work involves the transfer of scientific information and training between scientists at SDBRI with scientists in Australia, Italy and across the US. A Staff Scientist from India receives salary & benefits while being trained at SDBRI to better understand pathways that lead to diabetes using cellular, molecular and biochemical techniques. OTHER PROGRAM SERVICES 6: Systemic Lupus Erythematosus (SLE):SLE is caused by the immune system as it attacks the bodys tissue. Although there is a clear genetic predisposition to SLE, environmental factors also contribute to disease development. Ongoing work at SDBRI is focused on how genetic factors combine with virus infection and silica inhalation to cause SLE. It is hoped that understanding how the combination of these elements contribute to the development of SLE will provide information that can be used to develop therapies that block these interactions and the resulting disease. OTHER PROGRAM SERVICES 7: 7. Parkinsons DiseaseParkinsons disease (PD) is a neurodegenerative disorder that affects approximately 1% of the population over the age of 60. In the U.S. alone about 50,000 new cases are reported annually. It is believed that PD is caused by a combination of environmental and genetic factors. Scientists at SDBRI are working on the idea that allergic reactions represent an important environmental component in making people more susceptible to the development of PD. If this is true, components of the allergic response might be used as novel therapeutic targets to prevent PD or reduce its progression. Form 990, Part VI, Section B, Line 11b Form 990, its accompanying schedules and statements, and its corresponding stateinformation return are reviewed by the Board of Directors in advance of filing.Trustees have ample opportunity to ask questions and confirm their understanding andacceptance of the returns. Form 990, Part VI, Section B, Line 12c All decisions made by the Board of Directors are reviewed and assessed vis-a-vis theorganization's conflict of interest policy to determine any potential and/or actualconfilcts of interest. Interested trustees recuse themselves from discussion andvoting on any matter where a conflict of interest is determined to exist. Form 990, Part VI, Section B, Line 15a The process for determining the compensation of the CEO includes review andapproval by the Board of Directors, review of comparability data, andcontemporaneous substantiation. The Board of Directors' decision, inthis regard, is documented in the board minutes. Form 990, Part VI, Section B, Line 15b The process for determining the compensation of other officers and key employees includs review and approval by the Board of Directors, review of comparability data, and contemporaneous substantiation. The Board of Directors' decision, inthis regard, is documented in meeting minutes. Form 990, Part VI, Section C, Line 19 The institute makes its governing documents, conflicts of interest policy, and financial statements available to the public upon request.